What is CJC-1295 No DAC + Ipamorelin? A Research Guide.

The listing combines a GHRH-related peptide described as CJC-1295 No DAC with ipamorelin, a growth-hormone secretagogue. The No-DAC designation matters: it distinguishes the listing from the long-acting CJC-1295 material used in the cited clinical paper.[1]

GHRH-related signalling and growth-hormone-secretagogue signalling are different pathways investigated for hormone release. The No-DAC label matters because the long-acting CJC-1295 development program used a modification affecting duration of exposure. Ipamorelin was separately characterized as a pentapeptide with GHRP-like receptor activity in experimental systems. Combining these biological descriptions is a rationale for research, not evidence of clinical synergy or equivalent pharmacology between DAC and No-DAC materials.[1][2]

The CJC-1295 human study examines prolonged hormone-related responses to a long-acting analogue. The ipamorelin paper characterizes that compound separately. Neither study tests the exact No-DAC combination sold in this listing.[1]

The 2006 CJC-1295 publication describes two randomized, placebo-controlled, double-blind ascending-exposure studies lasting 28 and 49 days in healthy adults. It measured GH and IGF-I responses to the long-acting analogue, not the No-DAC blend. The corrected 1998 ipamorelin source reports pituitary-cell, rat and swine experiments. Neither paper evaluates this exact combined preparation. Their different materials and endpoints must remain visible in any comparison.[1][2]

Activity at complementary signalling pathways does not prove synergistic clinical benefit. Differences in molecular identity, timing, exposure and formulation prevent direct transfer of single-component results to a combination.[1][2]

The afiya composition reference describes a 1:1 blend for known sizes, but a supplier-provided composition is not clinical evidence or independent batch verification. This guide provides no hormone-use or administration advice.

A report of no serious adverse reactions in a short study of DAC-modified CJC-1295 is not a safety conclusion for No-DAC CJC-1295 plus ipamorelin. Hormone-related responses are biological measurements, not proof of better body composition or performance. Interactions and formulation-specific effects require direct combination evidence.[1][2]